Daily Respiratory Research Analysis
Analyzed 68 papers and selected 3 impactful papers.
Summary
Three high-impact respiratory studies stand out today: two mechanistic antibody papers that advance vaccine and therapeutic design against influenza B and sarbecoviruses, and a randomized trial showing a WeChat-integrated cessation program outperforms a quitline in China. Together, they span immunologic breadth against viral drift and scalable digital health to reduce smoking-related respiratory burden.
Research Themes
- Broadly neutralizing antibodies and vaccine design against respiratory viruses
- Pan-sarbecovirus immunity via guided affinity maturation
- Digital health for smoking cessation and respiratory risk reduction
Selected Articles
1. Human monoclonal antibodies isolated after seasonal vaccination broadly neutralize antigenically drifted influenza B viruses.
Post-2019 influenza B strains escape several prior bnAbs, but two new human bnAbs (CAV-CF22, CAV-CH76) isolated after quadrivalent vaccination broadly neutralize and protect against contemporary Victoria and Yamagata lineages. Structural analyses show HCDR3-mediated receptor-binding-site mimicry that is resilient to K136E drift, informing drift-resistant vaccine and antibody design.
Impact: This paper identifies drift-resilient neutralizing solutions to a rapidly evolving respiratory virus, combining human mAb discovery, in vivo protection, and structural mechanisms. It directly informs next-generation influenza B vaccines and therapeutic antibodies.
Clinical Implications: Guides immunogen design toward conserved RBS features and supports development of bnAb therapeutics robust to K136E drift; suggests surveillance of K136E as a marker of vaccine escape. Translation could reduce seasonal vaccine mismatch for influenza B.
Key Findings
- Post-2019 IBV strains escaped several previously identified head-directed bnAbs.
- Two new human bnAbs (CAV-CF22, CAV-CH76) broadly neutralized Victoria and Yamagata lineages and conferred in vivo protection.
- Fixation of K136E in Victoria HA disrupted many prior antibody epitopes.
- High-resolution structures showed HCDR3 insertion into the RBS to mimic sialic acid, explaining breadth and drift resilience.
Methodological Strengths
- Integration of human mAb isolation with in vitro neutralization, in vivo protection, phylogenetics, and high-resolution structural biology.
- Use of contemporary, post-2019 drifted clinical IBV strains to assess breadth and escape.
Limitations
- Preclinical nature without human efficacy data for the bnAbs.
- Limited number of bnAbs characterized; future drift patterns beyond K136E may still affect breadth.
Future Directions: Design and test RBS-mimicking immunogens and evaluate these bnAbs and vaccine concepts in clinical studies; monitor HA-136 variants for impact on antibody breadth.
Antigenic drift in hemagglutinin (HA) enables influenza viruses to escape host immunity. Elucidating molecular features of antigenic drift is essential for updating seasonal vaccines and pandemic preparedness. Here, we found that influenza B viruses (IBVs) isolated after 2019 escaped neutralization by several previously identified broadly neutralizing monoclonal antibodies (bnAbs). Meanwhile, we identified two IBV bnAbs, CAV-CF22 and CAV-CH76, isolated via quadrivalent vaccine. They exhibited broad neutralizing activity against Victoria- and Yamagata-lineage viruses in vitro and protected in vivo against contemporary Victoria and Yamagata strains. Phylogenetic and structural analysis revealed fixation of K136E in post-2019 Victoria HA, disrupting epitopes targeted by most previously characterized head-directed IBV-monoclonal antibodies (mAbs). High-resolution structures reveal that, rather than engaging K136, CAV-CF22 and CAV-CH76 insert HCDR3 into the receptor-binding site (RBS) to sterically mimic sialic acid. The conservation of epitope residues underlies the antibodies' broad neutralizing activity against IBV and informs antibody- and vaccine-design strategies that are resilient to recent IBV drift.
2. In vivo evolution of antibody CR3022 expands cross-neutralization of SARS-CoV-2 variants and informs pan-sarbecovirus immunity.
Using Ig-humanized mice expressing the CR3022 germline heavy chain, sequential SARS-CoV/SARS-CoV-2 immunization drove somatic hypermutation and convergent evolution to CR3022-like antibodies with expanded breadth against divergent sarbecoviruses. Structural data indicate enhanced affinity via increased polar/electrostatic interactions, and immunization intensity modulated epitope targeting.
Impact: It provides an in vivo blueprint for steering affinity maturation toward CR3022-like breadth, directly informing rational vaccine strategies for pan-sarbecovirus protection.
Clinical Implications: Supports sequential-immunization strategies to elicit cross-sarbecovirus antibodies; informs immunogen design prioritizing CR3022-like epitopes to enhance breadth against current and potential future sarbecoviruses.
Key Findings
- Ig-humanized mice expressing CR3022 germline underwent SHM-driven convergent evolution after SARS-CoV/SARS-CoV-2 sequential immunization, yielding CR3022-like antibodies with expanded breadth.
- Prime-boost favored CR3022-epitope targeting, whereas intensive vaccination shifted responses to other epitopes.
- X-ray structures showed enhanced affinity via increased polar and electrostatic interactions in SARS-CoV-2-neutralizing CR3022-like antibodies.
- Minor affinity shifts through SHM can adapt CR3022-like clones to key variants and divergent sarbecoviruses.
Methodological Strengths
- In vivo humanized antibody maturation model coupled with structural biology to mechanistically explain breadth.
- Systematic comparison of vaccination regimens to dissect epitope targeting and adaptation.
Limitations
- Mouse humanized model may not fully recapitulate human B-cell repertoire and germinal center dynamics.
- Durability of responses and protection against live viral challenge across diverse sarbecoviruses were not detailed in the abstract.
Future Directions: Evaluate sequential-immunization strategies and CR3022-epitope-focused immunogens in nonhuman primates and early phase human trials; quantify durability and protection breadth.
The epitope that monoclonal CR3022 binds to represents a promising target for broad protection against a wide range of human and zoonotic coronaviruses. We develop a powerful model to evaluate antibody affinity maturation in vivo using immunoglobulin (Ig)-humanized mice that express the predicted germline heavy chain of antibody CR3022. Severe acute respiratory syndrome coronavirus (SARS-CoV)/SARS-CoV-2 sequential immunization leads to the convergent evolution of the germline CR3022 through somatic hypermutation (SHM), resembling the affinity-matured CR3022 from a human but now also adapting to key variants and divergent sarbecoviruses. While simple prime-boost strategies drive CR3022-epitope targeting, an intensive vaccination protocol elicits dominant responses to other epitopes. X-ray crystal structures reveal that SARS-CoV-2-neutralizing CR3022-like antibodies exhibit enhanced affinity by increasing polar and electrostatic interactions. Overall, these findings show that CR3022-like clones can be readily adapted through SHM to increase breadth and potency to sarbecoviruses by relatively minor shifts in affinity with appropriate vaccination strategies.
3. Efficacy and long-term engagement of a WeChat-integrated modality versus a traditional quitline on smoking cessation in China: a randomised controlled trial.
In an open-label RCT of 460 smokers in Beijing, a multicomponent WeChat-integrated program achieved higher biochemically verified 1-month abstinence than a quitline (41.5% vs 27.9%). Engagement peaked early and waned, but early intensity predicted sustained abstinence up to 12 months.
Impact: Demonstrates superior short-term efficacy of a scalable, theory-guided digital intervention in the world’s largest smoking population, with actionable insights on engagement dynamics predicting long-term outcomes.
Clinical Implications: Health systems can integrate WeChat-like multicomponent support alongside pharmacotherapy to boost early abstinence; program design should emphasize maximizing early engagement and consider strategies to sustain use over time.
Key Findings
- Biochemically verified 7-day point prevalence abstinence at 1 month was higher with WeChat-integrated intervention vs quitline (41.5% vs 27.9%; RR 1.49, 95% CI 1.14-1.95; p=0.004).
- Engagement with the mini-program peaked in month 1 (99.0%) and declined to 6.7% by month 8.
- Greater early (first 3 months) usage was dose-dependently associated with higher 3-, 6-, and 12-month abstinence rates.
Methodological Strengths
- Randomized controlled design with modified intention-to-treat analysis and biochemical verification of abstinence.
- Pre-registered protocol with multiple follow-ups to 12 months and standardized NRT provision across arms.
Limitations
- Open-label design and reliance on a country-specific platform may limit generalizability.
- Engagement decay over time; mITT excluded some randomized participants (414/460 analyzed).
Future Directions: Test strategies to sustain engagement beyond 3 months, evaluate cost-effectiveness and scalability across regions/platforms, and assess integration with clinical pathways and diverse pharmacotherapies.
BACKGROUND: Digital health interventions offer a promising opportunity to innovate traditional cessation services. Multi-component digital approaches show potential for greater effectiveness than traditional methods, though optimal integration strategies and engagement dynamics are still unclear. This study evaluated 'Way to Quit' (WQ)-a theory-guided, integrated modality based on WeChat (a popular social media platform)-compared with a quitline, with particular attention to long-term engagement and its impact on abstinence. METHODS: A two-arm, open-label, randomised controlled trial was conducted in Beijing, China, from December 1, 2022 to June 13, 2024. We recruited adult smokers intending to quit within one month via online advertisements. Participants were randomly assigned (1:1; using various block sizes) to either a multicomponent WeChat-based intervention (WQ)-integrating a mini-programme (application-like service), a chat group (peer support) and an official account (information channel)-or telephone counselling (Quitline), both lasting four weeks (one pre-quit week and three post-quit weeks). All participants received a four-week supply of nicotine gum by mail for on-demand use. Follow-up assessments were completed at one, three, six, and twelve months after the initiation of the intervention via telephone or online. The primary outcome was biochemically verified 7-day point prevalence abstinence (PPA) at one month. Analyses followed a modified intention-to-treat (mITT) approach. RESULTS: A total of 460 adult smokers were enrolled and randomised (WQ: n = 230; Quitline: n = 230), with 414 included in the mITT analysis (WQ: 195; Quitline: 219). At one month, biochemically verified 7-day PPA was 41.5% in the WQ group and 27.9% in the Quitline group (RR, 1.49; 95% CI, 1.14-1.95; P = 0.004). Mini-programme engagement peaked initially but declined after three months, from 99.0% in one month to 6.7% in eight months. Greater usage during the first three months was dose-dependently associated with higher long-term abstinence rates (3-, 6-, and 12-month 7-day PPA), with all P CONCLUSIONS: The WQ modality showed superior short-term efficacy compared with the quitline, supporting its potential as an alternative or adjunct to traditional cessation services. Although long-term engagement remained challenging, early engagement intensity within the first three months strongly predicted twelve-month abstinence. TRIAL REGISTRATION: The trial was preregistered at Chinese Clinical Trial Registry Identifier (https://www.chictr.org.cn/bin/project/edit?pid=179013, ID: ChiCTR2200066427). Registration date: December 5, 2022.